Validation of the 'Marburg bone bank system' for thermodisinfection of allogenic femoral head transplants using selected bacteria, fungi, and spores

Biologicals

Volumn 31, Issue 4, 2003, Pages 287-294

  Pruss, Axel ^a   Seibold, Michael ^b   Benedix, Frank ^a   Frommelt, Lars ^c   Von Garrel, Thomas ^d   Gürtler, Lutz ^e   Dörffel, Yvonne ^a   Pauli, Georg ^b   Göbel, Ulf Berthold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c ENDO Klinik   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Bone bank; Bone transplant; Lobator; Pathogen transmission; Thermodisinfection; Tissue banking

Indexed keywords

ARTICLE; ASPERGILLUS NIGER; BACILLUS SUBTILIS; BACTERIAL SPORE; BACTERIOSTASIS; BACTERIUM; BACTERIUM CULTURE; BONE ALLOGRAFT; CANDIDA ALBICANS; CLOSTRIDIUM SPOROGENES; CONTROLLED STUDY; DISINFECTION; ENTEROCOCCUS FAECIUM; FEMUR HEAD; FEMUR HEAD PROSTHESIS; FUNGUS; FUNGUS CULTURE; HEALTH CARE FACILITY; HEAT TREATMENT; HUMAN; HUMAN TISSUE; MYCOBACTERIUM TERRAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REDUCTION; STANDARD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VALIDATION PROCESS;

ASPERGILLUS; ASPERGILLUS NIGER; BACILLUS SUBTILIS; CANDIDA; CANDIDA ALBICANS; CLOSTRIDIUM; CLOSTRIDIUM SPOROGENES; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; FUNGI; MYCOBACTERIUM; MYCOBACTERIUM TERRAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0242407429     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2003.08.002     Document Type: Article

References (45)

1. Kakaiya R., Miller W.V., Gudino M.D. Tissue transplant transmitted infections. Transfusion. 31:(3):1991;277-284.
2. Wilmes E., Gürtler L., Wolow H. Zur Übertragung von HIV-Infektionen durch allogene Transplantate. Laryngo Rhino Otol. 66:1987;332-334.
3. Transmission of HIV through bone transplantation: case report and public health recommendations. MMWR. 37:1988;597-599.
4. Habal M.B., Reddi A.H. Bone grafts and bone substitutes. 1992;Saunders, Philadelphia/London/Toronto.
5. Hepatitis C virus transmission from an antibody-negative organ and tissue donor. MMWR. 52:2003;273-276.
6. von Garrel T., Gotzen L. Allogene Knochentransplantation und Knochenbanking. Unfallchirurg. 101:1998;713-727.
7. Jerosch J., Castro W.H.M., Granrath M., Rosin H. Knochenbanken in der BRD. Unfallchirurg. 93:1990;334-338.
8. Husted H., Kramhoft M.U. Microbiology of femoral head grafts in bone banks. Ugeskr Laeger. 158:(44):1996;6260-6262.
9. Veen M.R., Bloem R.M., Petit P.L. Sensitivity and negative predictive value of swab cultures in musculoskeletal allograft procurement. Clin Orthop. 300:1994;259-263.
10. Ritter M.A., French M.L., Hart J.B. Microbiological studies in a horizontal wall-less laminar air-flow operating room during actual surgery. Clin Orthop. 97:1973;16-18.
11. Deijkers R.L., Bloem R.M., Petit P.L., Brand R., Vehmeyer S.B., Veen M.R. Contamination of bone allografts: analysis of incidence and predisposing factors. J Bone Joint Surg Br. 79:(1):1997;161-166.
12. Fitzgerald R.H. Jr, Washington J.A. 2nd. Contamination of the operative wound. Orthop Clin North Am. 6:(4):1975;1105-1114.
13. Bettin D., Buchholz B., Dietl K.H., Harms C. The analysis of bacterial results in the kidney perfusion fluid and bone allografts in human multiorgan donors. Cell and Tissue Banking. 1:2000;313-316.
14. Regel G., Südkamp N.P., Illgner A., Buchenau A., Tscherne H. 15 Jahre allogene Knochentransplantation. [15 years allogeneic bone transplantation. Indications, treatment and results]. Unfallchirurg. 95:(1):1992;1-8.
15. Südkamp N.P., Haas N.P., Tempka A., Veuskens A., Kirchhoff A., Tscherne H. Indikation und Häufigkeit von Spongiosatransplantationen bei offenen Frakturen: Analyse von 470 offenen Frakturen. [Indications and incidence of cancellous bone transplantation in open fractures: analysis of 470 open fractures]. Akt Traumatologie. 23:(4):1993;169-177.
16. Tomford W.W., Starkweather R.J., Goldman M.H. A study of the clinical incidence of infection in the use of banked allograft bone. J Bone Joint Surg Am. 63:(2):1981;244-248.
17. Lord C.F., Gebhardt M.C., Tomford W.W., Mankin H.J. Infection in bone allografts. Incidence, nature, and treatment. J Bone Joint Surg Am. 70:(3):1988;369-376.
18. James J.I.P. Tuberculosis transmitted by bone bank. J Bone Joint Surg Br. 35:1953;578.
19. Richtlinien zum Führen einer Knochenbank. Deutsches Ärzteblatt. 98:(15):2001;A1011-1016.
20. Update: Allograft-associated bacterial infections - United States 2002. MMWR. 51:(10):2002;207-210.
21. Creutzfeldt-Jakob disease in a patient receiving a cadeveric dura mater graft. MMWR. 36:(21):1987;324-325.
22. Creutzfeldt-Jakob disease in a second patient who received a cadeveric dura mater graft. MMWR. 38:(3):1989;37-38.
23. Duffy P., Wolf J., Collins G., De Voe A.G., Streeten B., Cowen D. Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med. 290:1974;692-693.
24. Thadani V., Penar P.L., Partington J., Kalb R., Janssen R., Schonberger L.B., et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg. 69:(5):1988;766-769.
25. EMEA/410/01/rev 1. Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents viahuman and veterinary medicinal products. Committee for proprietary medicinal products (CPMP) 2001, London.
26. Frommelt L. Mikrobiologische Aspekte der allogenen Knochentransplantation. 63. Jahrestagung, Deutsche Gesellschaft fürUnfallchirurgie e.V.; November 17-20, 1999, Berlin.
27. Sogal A., Tofe A.J. Risk assessment of bovine spongioform encephalopathy transmission through bone graft material derived from bovine bone used for dental applications. J Periodontol. 70:(9):1999;1053-1063.
28. Fitzgerald R.H. Jr, Peterson L.F., Washington J.A. 2nd, Van Scoy R.E., Coventry M.B. Bacterial colonization of wounds and sepsis in total hip arthroplasty. J Bone Joint Surg Am. 55:(6):1973;1242-1250.
29. Europäische Norm EN 1040. Chemische Desinfektionsmittel und Antiseptika, Bakterizide Wirkung (Basistest). Prüfverfahren und Anforderungen. [Chemical disinfectants and antiseptics - Basic bactericidal activity] CEN (Europäisches Kommitee fürNormung) 1997, Brüssel.
30. prEN 13624. Quantitativer Suspensionsversuch zur Prüfung der fungiziden Wirkung chemischer Desinfektionsmittel für Instrumente im humanmedizinischen Bereich. [Quantitative suspension test for evaluation of fungicidal activity of chemical disinfectants for instruments used in the medical area]. Deutsches Institut für Normung (DIN), 1999.
31. Pruss A., Kao M., von Garrel T., Frommelt L., Gürtler L., Benedix F., et al. Virus inactivation in bone tissue transplants (femoral heads) by moist heat with the 'Marburg Bone Bank System'. Biologicals. 31:2002;75-82.
32. Knaepler H. Thermische Spongiosa - Desinfektion. MedReport. 33:1995;2-3.
33. Knaepler H., von Garrel T., Gotzen L. Untersuchungen zur Desinfektion und Sterilisation allogener Knochentransplantate. Unfallchirurg (Hefte). 235:1994;1-101.
34. Knaepler H., von Garrel T., Seipp H.M., Ascherl R. Experimentelle und klinische Untersuchungen zur thermischen Desinfektionallogener Knochentransplantate und deren Einbauverhalten. Orthop Praxis. 1:1992;23-27.
35. Knaepler H., von Garrel T., Seipp H.M., Ascherl R. Experimentelle Untersuchungen zur thermischen Desinfektion und Sterilisation allogener Knochentransplantate und deren Auswirkungen auf die biologische Wertigkeit. [Experimental studies of thermal disinfection and sterilization of allogeneic bone transplants and their effects on biological viability]. Unfallchirurg. 95:(10):1992;477-484.
36. von Garrel T., Knaepler H., Gürtler L. Untersuchungen zur Inaktivierung von HIV-1 in humanen Femurköpfen durch Verwendung eines thermischen Desinfektionssystems Lobator SD-1. [Inactivation of HIV-1 in human femur heads using a heat disinfection system (Lobator SD-1)]. Unfallchirurg. 100:(5):1997;375-381.
37. Anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma. Bundesanzeiger. 84:1994;4742-4744.
38. Bekanntmachung zu allogenen Gewebetransplantaten. Bundesanzeiger. 75:1996;4670.
39. CPMP. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses. Final version BWP/268/95, London, February 1996.
40. CEN. Sterilization of medical devices utilizing tissues-validation of the inactivation of viruses and other transmissible agents. Final version 316/WG3/N-02, Brüssel, 1994.
41. Pruss A., Baumann B., Seibold M., Kao M., Tintelnot K., von Versen R., et al. Validation of the sterilization procedure of allogeneic avital bone transplants using peracetic acid-ethanol. Biologicals. 29:2001;59-66.
42. Doppelt S.H., Tomford W.W., Lucas A.D., Mankin H.J. Operational and financial aspects of a hospital bone bank. J Bone Joint Surg Am. 63:(9):1981;1472-1481.
43. Chapman P.G., Villar R.N. The bacteriology of bone allografts. J Bone Joint Surg Br. 74:(3):1992;398-399.
44. Barrios R.H., Leyes M., Amillo S., Oteiza C. Bacterial contamination of allografts. Acta Orthop Belg. 60:(2):1994;152-154.
45. Martinez O. Microbiologic screening of cadaver donors and tissues for transplantation. 26th Annual Meeting, American Association of Tissue Banks. Boston, Massachusetts, August 2002.